Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarket [Seeking Alpha]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Seeking Alpha
Protalix out-licenses Fabry candidate PRX-102 to Chiesi; shares ahead 38% premarketNano cap Protalix BioTherapeutics (NYSEMKT:PLX) jumps38% premarket on robust volume in response to its ex-U.S. license and collaborationagreement with Chiesi Farmaceutici S.p.A. for PRX-102 for the treatment of Fabry disease.Under the terms of the agreement, Protalix will receive $25M upfront, up to $25M for development costs (capped at $10M/yr), up to $320M in milestones and tiered royalties from 15 - 35% on net sales.Chiesi receives exclusive rights to PLX-102 for all markets outside of the U.S.PRX-102 is chemically modified version of a recombinant therapeutic enzyme called alpha-galactosidase A.Fabry disease is an inherited disorder caused by mutations in the gene that codes for alpha-galactosidase A. It is characterized by the buildup of Gb3 in the body's cells.Previously:Protalix Bio's PRX-102 shows encouraging effect in Fabry models compared to enzyme replacement therapies; shares ahead 7% premar
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics, Inc. (NYSE: PLX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 [Yahoo! Finance]Yahoo! Finance
PLX
Earnings
- 11/6/23 - Beat
PLX
Sec Filings
- 4/3/24 - Form 4
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- PLX's page on the SEC website